Please wait

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Name of Issuer)

(Title of Class of Securities)

(CUSIP Number)

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13D/A 0001104659-20-138040 0001818245 XXXXXXXX LIVE 6 Common Stock, par value $0.0001 per share 09/22/2025 false 0001742927 76152G100 REVIVA PHARMACEUTICALS HOLDINGS, INC. 10080 N. WOLFE ROAD, SUITE SW3-200 CUPERTINO CA 95014 Laxminarayan Bhat 408-501-8881 10080 N. Wolfe Rd., Suite SW3-200 Cupertino CA 95014 0001818245 N Bhat Laxminarayan OO N X1 3352177.00 328697.00 3352177.00 328697.00 3680874.00 N 3.8 IN See Item 5 for additional information. Common Stock, par value $0.0001 per share REVIVA PHARMACEUTICALS HOLDINGS, INC. 10080 N. WOLFE ROAD, SUITE SW3-200 CUPERTINO CA 95014 This Amendment No. 6 (this Amendment) amends and supplements the Schedule 13D filed on December 21, 2020, as amended and supplemented by Amendment No. 1 filed on May 5, 2023, Amendment No. 2 filed on February 16, 2024, Amendment No. 3 filed on August 23, 2024, Amendment No. 4 filed on December 20, 2024 and Amendment No. 5 filed on July 1, 2025 (the Schedule 13D), by Dr. Laxminarayan Bhat (the Reporting Person) relating to the common stock, par value $0.0001 per share (Common Stock), of Reviva Pharmaceuticals Holdings, Inc., a Delaware corporation (the Issuer). Capitalized terms used but not defined in this Amendment have the respective meanings ascribed to such terms in the Schedule 13D. All references in the Schedule 13D and this Amendment to the Schedule 13D shall be deemed to refer to the Schedule 13D as amended and supplemented by this Amendment. As of the filing date of this Amendment (the Filing Date), for purposes of Rule 13d-3 promulgated under the Act, the Reporting Person is the beneficial owner of an aggregate of 3,680,874 shares of Common Stock, which represents approximately 3.8% of the outstanding shares of Common Stock, based on 96,337,119 shares of Common Stock outstanding as of September 22, 2025, as reported directly by the Issuer to the Reporting Person. Of the 3,680,874 shares of Common Stock reported as beneficially owned by the Reporting Person herein, for purposes of Rule 13d-3 under the Act, the Reporting Person: (A) has sole voting power and dispositive power with respect to an aggregate of 3,352,177 of such shares, consisting of (i) 2,478,856 shares of Common Stock held by the Reporting Person, and (ii) 873,321 shares of Common Stock issuable upon the exercise of options held by the Reporting Person that are exercisable or will be exercisable within 60 days of the Filing Date; and (B) may be deemed to share voting power and dispositive power with respect to an aggregate of 328,697 of such shares, consisting of (i) 5,388 shares of Common Stock held by the Reporting Person's spouse, and (ii) 323,309 shares of Common Stock issuable upon the exercise of options held by the Reporting Person's spouse that are exercisable or will be exercisable within 60 days of the Filing Date. The amount of shares reported as beneficially owned by the Reporting Person excludes (i) 247,130 shares of Common Stock underlying unvested options held by the Reporting Person and (ii) 86,034 shares of Common Stock underlying unvested options held by the Reporting Person's spouse, in each case that are not exercisable within 60 days of the Filing Date. The Reporting Person has not effected any transactions in the Common Stock or securities convertible into, exercisable for or exchangeable for, shares of Common Stock during the period commencing 60 days prior to the Filing Date. Except as otherwise reported herein, no person or entity other than the Reporting Person has the right to receive, or the power to direct the receipt of dividends from, or the proceeds from the sale of the shares of the Common Stock reported on this Schedule 13D. On September 22, 2025, based on the number of shares of Common Stock outstanding as of such date as described in Item 5(a) of this Amendment, the Reporting Person ceased to be the beneficial owner of more than five percent of the Common Stock and is no longer subject to the reporting requirements of Rule 13d-1(a) promulgated under the Act. Bhat Laxminarayan /s/ Laxminarayan Bhat Laxminarayan Bhat 09/24/2025